Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (9)

2020

  1. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

    Journal of Diabetes Science and Technology, Vol. 15, Núm. 3, pp. 636-645

2019

  1. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 6, pp. 1506-1512

  2. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy

    Diabetes, Obesity and Metabolism, Vol. 21, Núm. 12, pp. 2643-2650

2018

  1. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The dual VII randomized clinical trial

    Diabetes Care, Vol. 41, Núm. 5, pp. 1009-1016

2013

  1. Comparative effects of teriparatide and risedronate in glucocorticoid- induced osteoporosis in men: 18-month results of the EuroGIOPs trial

    Journal of Bone and Mineral Research, Vol. 28, Núm. 6, pp. 1355-1368

  2. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

    Osteoporosis International, Vol. 24, Núm. 12, pp. 2971-2981

2010

  1. Back pain during different sequential treatment regimens of teriparatide: Results from EUROFORS

    Current Medical Research and Opinion, Vol. 26, Núm. 8, pp. 1799-1807

2008

  1. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

    Journal of Clinical Endocrinology and Metabolism, Vol. 93, Núm. 3, pp. 852-860

2005

  1. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1

    Maturitas, Vol. 52, Núm. 2, pp. 87-101